Arkadios Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Arkadios Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.8K	Sell	11,650 -23,556	-67%	-$78.4K	﹤0.01%	1725
2026 Q1	$108K	Sell	35,206 -3,634	-9%	-$14K	﹤0.01%	1616
2025 Q4	$159K	Sell	38,840 -6,612	-15%	-$32.7K	﹤0.01%	1473
2025 Q3	$222K	Buy	45,452 +6,796	+18%	+$35.7K	0.01%	1314
2025 Q2	$196K	Buy	+38,656	New	+$190K	0.01%	1219
2025 Q1	–	Sell	-12,431	Closed	-$84K	–	1184
2024 Q4	$84K	Buy	+12,431	New	+$83.6K	﹤0.01%	893

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arkadios Wealth Advisors's RXRX Position: Q2 2026 in Review

Arkadios Wealth Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 67% in Q2 2026, selling an estimated $78.4K and leaving 11,650 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Arkadios Wealth Advisors first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $222K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Arkadios Wealth Advisors held 11,650 shares of Recursion Pharmaceuticals worth $42.8K as of Q2 2026.
Arkadios Wealth Advisors sold 23,556 Recursion Pharmaceuticals shares in Q2 2026, an estimated $78.4K.
Recursion Pharmaceuticals made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #1725 holding.
Arkadios Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Arkadios Wealth Advisors's Recursion Pharmaceuticals position peaked at $222K in Q3 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.